Alumis (NASDAQ:ALMS) Insider Mark Christopher Bradley Sells 2,572 Shares

Alumis Inc. (NASDAQ:ALMS) insider Mark Christopher Bradley sold 2,572 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $67,823.64. Following the sale, the insider directly owned 48,533 shares in the company, valued at $1,279,815.21. The trade was a 5.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alumis Price Performance

ALMS opened at $27.12 on Thursday. The firm has a fifty day moving average price of $25.37 and a 200 day moving average price of $25.22. Alumis Inc. has a 1 year low of $3.76 and a 1 year high of $31.35. The stock has a market cap of $3.46 billion, a P/E ratio of -13.70 and a beta of -0.69.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The firm had revenue of $1.74 million during the quarter, compared to analysts’ expectations of $2.10 million. Equities analysts expect that Alumis Inc. will post -2.87 EPS for the current year.

Institutional Investors Weigh In On Alumis

Several institutional investors and hedge funds have recently added to or reduced their stakes in ALMS. Samsara Biocapital LLC grew its holdings in shares of Alumis by 19.9% during the fourth quarter. Samsara Biocapital LLC now owns 5,756,984 shares of the company’s stock worth $56,188,000 after buying an additional 955,614 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Alumis by 18.4% in the third quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock valued at $16,078,000 after buying an additional 625,404 shares during the last quarter. Cormorant Asset Management LP lifted its stake in shares of Alumis by 69.3% in the fourth quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock worth $35,483,000 after buying an additional 1,488,200 shares in the last quarter. Octagon Capital Advisors LP boosted its position in Alumis by 11.9% during the first quarter. Octagon Capital Advisors LP now owns 2,830,700 shares of the company’s stock worth $62,360,000 after acquiring an additional 300,000 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new position in Alumis during the fourth quarter worth about $23,443,000.

Wall Street Analysts Forecast Growth

ALMS has been the topic of several research analyst reports. Wall Street Zen lowered Alumis from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Guggenheim increased their target price on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, May 15th. HC Wainwright reissued a “neutral” rating and issued a $25.00 price target on shares of Alumis in a report on Monday. Chardan Capital increased their price objective on shares of Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, May 19th. Finally, Wells Fargo & Company lifted their target price on shares of Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $40.30.

Key Alumis News

Here are the key news stories impacting Alumis this week:

• Neutral Sentiment: HC Wainwright reaffirmed its “Neutral” rating on Alumis, indicating the analyst does not currently see a strong enough catalyst to support a more bullish view. HC Wainwright Reaffirms Neutral Rating for Alumis
• Negative Sentiment: Six company insiders, including CFO John R. Schroer, sold a combined 14,953 shares of Alumis on August 3 at an average price of $26.37, generating approximately $394,311 in proceeds. The sales reduced individual holdings by roughly 1.28% to 12.28%; the CFO’s position declined 11.72%. While insider sales can reflect personal financial planning rather than a change in business outlook, the concentration of sales may weigh on investor sentiment. The transactions were reported in SEC filings for Read More., Read More., Read More., Read More., Read More., and Read More..

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.